摘要
目的:观察灯盏花素对糖尿病大鼠模型血糖、血脂、转化生长因子β表达的影响。方法:实验于2003-10在天津市肝胆病研究所完成。选取20只大鼠采用四氧嘧啶化学诱发法制作糖尿病大鼠模型。将20只大鼠随机分为模型组及治疗组,另选10只健康大鼠作为对照组。治疗组用灯盏花素按照(3.35μg/g体质量)的药量用10mL注射器吸取中药生理盐水溶解液灌胃,模型组及对照组用等量生理盐水灌胃,1次/d(给药方案为预先设计)。结果:①3组血动态检测结果化验结果表明,除正常对照组外,3d至120d其他两组血糖值差异无显著意义(P>0.05)。②三酰甘油及高密度脂蛋白3组比较其结果差异无显著意义(P>0.05)。③胆固醇、血清白蛋白、血肌酐、尿素氮、肌酐清除率化验结果及24h尿蛋白、24h尿肌酐、24h尿白蛋白、血清IV型胶原检测值比较结果表明,治疗组均显著低于模型组(P<0.01)。④大鼠肾小球组织转化生长因子β阳性产物检测,治疗组低于模型组(15.23±9.46),(23.31±11.42)μg/L,但仍高于对照组(11.65±7.43),3组间比较差异显著(P<0.05)。结论:灯盏花素控制糖尿病微血管并发症的发生,与降低血糖,血脂无关,抑制组织转化生长因子β可能是其发挥效应的主要途径之一。
AIM:To observe the influence of breviscapine on the blood glucose, blood lipid and expression of transforming growth factor beta (TGF-β) in rat model of diabetes. METHODS: The experiment was carried out in Tianjin Institute of Hepatology in October 2003.Twenty rats were made into alloxan-induced diabetic models, and then they were randomly divided into model group and treatment group,another 10 healthy rats were taken as controls (control group).Rats in the treatment group received gastric perfusion of breviscapine (3.35 μg/g body mass),which was dissolved in saline with 10 mL injector, and those in the model group and control group were treated with gastric perfusion of saline of the same volume, once a day (the program of administration was designed beforehand). RESULTS: ①The results of chemical analysis of the blood dynamic detection in the 3 groups showed that except the normal control group, the values of blood glucose from the 3rd to the 120th days were not significantly different between the other two groups (P >0.05). ②The triacylglycerol (TG) and high density lipoprotein (HDL) among the 3 groups were insignificantly different (P >0.05).③The results of chemical analysis of cholesterol (C),serum albumin, blood creatinine, blood uria nitrogen (BUN) and creatinine clearance rate, and the outcomes of detective comparison of 24-hour urine protein, 24-hour urine creatinine, 24-hour urine albumin and serum collagen type IV showed that those were significantly lower in the treatment group than in the control group (P< 0.01). ④The TGF-βpositive production of renal corpuscle tissue in the treatment group [(15.23±9.46) μg/L] was lower than that in the model group[(23.31±11.42) μg/L], but still higher than that in the control group [(11.65 ±7.43) μg/L], there were significant differences among the 3 groups(P< 0.05). CONCLUSION: Breviscapine can control the occurrence of diabetic microvascular complications, which is not correlated with the decreases of blood glucose and blood lipid.Inhibition of TGF-βmay be one of the main pathways for playing its role.
出处
《中国临床康复》
CSCD
北大核心
2005年第15期132-133,共2页
Chinese Journal of Clinical Rehabilitation
